ABC transporters and the blood-brain barrier

Current Pharmaceutical Design

Volumn 10, Issue 12, 2004, Pages 1295-1312

  Begley, David J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BREAST CANCER RESISTANCE PROTEIN; CYCLOSPORIN A; DEXAMETHASONE; DIGOXIN; DILTIAZEM; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; INDINAVIR; IVERMECTIN; LOPERAMIDE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; NELFINAVIR; NIFEDIPINE; ONDANSETRON; PACLITAXEL; PHENYTOIN; QUINIDINE; RANITIDINE; RAPAMYCIN; SAQUINAVIR; TACROLIMUS; UNINDEXED DRUG; VALINOMYCIN; VECURONIUM; VINBLASTINE; VINCRISTINE;

AMINO ACID SEQUENCE; AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG TRANSPORT; DRUG UPTAKE; GENE EXPRESSION; HUMAN; LIPID SOLUBILITY; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; RAT; REVIEW; SEQUENCE HOMOLOGY;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BLOOD-BRAIN BARRIER; BRAIN; BRAIN CHEMISTRY; HUMANS;

EID: 1642454475     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043384844     Document Type: Review

References (147)

1. Higgins C. ABC transporters from microorganisms to man. Ann Rev Cell Biol 1992; 8: 67-113.
2. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001; 11: 1156-1166.
3. Borst P, Oude ElferinkR. Mammalian ABC transporters in Health and disease. Ann Rev Biochem 2002; 71: 537-592.
4. Klein I, Sarkadi B, Váradi A. An inventory of the human ABC proteins. Biochim Biophys Acta 1999; 1461: 237-262.
5. Ghersi-Egea J-F, Strazielle, N. Choroid plexus transporters for drugs and other xenobiotics. J Drug Targ 2002; 11: 353-357.
6. Eisenblatter T, Galla H-J. A new multidrug resistance protein at the blood-brain barrier. Biochem Biophys Res Comm 2002; 293: 1273-1278.
7. Cooray H, Blackmore CG, Maskell L, Barrand MA. Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 2002; 13: 2059-2063.
8. Lee G, Dallas, S, Hong M, Bendayan R. Drug transporters in the central nervous system: Brain barriers and brain parenchymal considerations. Pharm Rev 2001; 53: 569-596.
9. Terasaki T, Hosoya K. The blood-brain efflux transporters as a detoxifying system for the brain. Adv Drug Deliv Rev 1999; 36: 195-209.
10. Kusuhara H, Sugiyama Y. Efflux transport systems for drugs at the blood-brain and blood cerebrospinal fluid barrier (Part 1). Drug Discov Today 2001; 6: 150-156.
11. Kusuhara H, Sugiyama Y. Efflux transport systems for drugs at the blood-brain and blood cerebrospinal fluid barrier (Part 2). Drug Discov Today 2001; 6: 206-212.
12. Begley D. Efflux mechanisms in the central nervous system: A powerful influence on drug distribution within the brain In: Sharma HS and Westman J Eds, Blood-Spinal Cord and Brain Barriers in Health and Disease Elsevier Science USA 2004; 83-97.
13. Sun H, Dai H, Shaik N, Elmquist WF. Drug efflux transporters in the CNS. Adv Drug Deliv Rev 2003; 55: 83-105.
14. Deely RG, Cole SP. Function, evolution and structure of multidrug resistance protein (MRP). Seminars in Cancer Biol 1997; 8: 193-204.
15. Hsu SIH, Cohen D, Kirchner LS, Hartstein M, Horwitz SB. Stuctural analysis of the mouse mdr1a (P-glycoprotein) promotor reveals the basis for differential transcripts heterogeneity in multidrug resistant J774.2 cells. Mol Cell Biol 1990; 10: 3596-3606.
16. Chin JE, Soffir R, Noonan KE, Choi KY, Roninson IB. Structure and expression of the human MDR (P-glycoprotein) gene family. Mol Cell Biol 1989: 9: 3808-3820.
17. Devault A, Gros P. Two members of the mouse mdr family confer multidrug resistance with overlapping but distinct drug specificities. Mol Cell Biol 1990; 1652-1663.
18. van der Bliek AM, Kooiman PM, Schneider C, Borst P. Sequence of mdr3 cDNA encoding a human P-glycoprotein. Gene 1998; 71: 401-411.
19. Ng WF, Sarangi F, Zastawany RL, Veintot-Drebot L, Ling V. Indentification of members of the P-glycoprotein multigene family. Mol Cell Biol 1989; 9: 1224-1232.
20. Smit JJM, Schinkel AH, Oude Elferinck RPJ, Groen AK, Wagenaar E, van Deemter L, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993; 75: 451-462.
21. Cordon Cardo C, O'Brien JP, Casals D, Ritman-Grauer L, Biedler JL, Melamed MR, et al. Proc Natl Acad Sci USA 1989; 86: 695-698.
22. Theibaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Immunohistochemical localisation in normal tissues of different epitopes in the multidrug transport protein P170: Evidence for localisation in brain capillaries and cross reactivity of one antibody with a muscle protein. J Histochem Cytochem 1989; 37: 159-164.
23. Tasuta T, Naito M, Oh-Hara T, Sugawara I, Tsuruo T. Functional involvement of P-glycoprotein in blood brain barrier. J Biol Chem 1992; 267: 20383-20391.
24. Stewart PA, Beliveau R, Rogers KA. Cellular localisation of P-glycoprotein recognised by MRK16 monoclonal antibody in brain and spinal cord. J Histochem Cytochem 1996; 44: 679-685.
25. Beaulieu É, Demeule M, Ghitescu L, Béliveau R. P-glycoprotein is stongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem J 1997; 326: 301-307.
26. Begley DJ, Khan EU, Rollinson C, Abbott NJ, Régina A, Roux F. The role of brain extracellular fluid production and efflux mechanisms in drug transport to the Brain In: Begley DJ, Bradbury MWB, Kreuter J. Eds, The Blood-brain barrier and drug delivery to the CNS New York, Dekker 2000; 93-108.
27. Demeule M, Régina A, Jodoin J, Laplante A, Dagenais C, Berthelet F, et al. Drug transport to the brain: Key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascular Pharm 2002; 38: 339-348.
28. Virgintino D, Robertson D, Errede, Benagiano V, Girqlamo F, Maiorano E, Roncali L, Bertossi M. Expression of P-glycoprotein in human cerebral cortex microvessels. J Histochem Cytochem 2002; 50: 1671-1676.
29. Rao VV, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli AC, et al. Choroid plexus epithelial expression of MDRIP-glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal fluid drug-permeability barrier. Proc Natl Acad Sci USA 1999; 96: 3900-3905.
30. Miller DS, Villalobos AR, Pritchard JB. Organic cation transport in rat choroid plexus cells studied by fluorescence microscopy. Am J Physiol 1999; 45: C955-C968.
31. Pardridge WM, Golden PL, Kang Y-S, Bickel U. Brain microvascular and astrocyte localisation of P-glycoprotein. J Neurochem 1997; 68: 1278-1285.
32. Golden PL, Pardridge WM. P-glycoprotein on astrocyte foot processes of unfixed isolated human brain capillaries. Brain Res 1999; 819: 143-146.
33. Schinkel A. P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Del Rev 1999; 36: 179-194.
34. Régina A, Koman A, Piciotti M, El Hafny B, Center MS, Bergman R, et al. Mrp1 multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J Neurochem 1998; 71: 705-715.
35. Schinkel AH, Smit JJM, van Telligen O, Beijnen JH, Wagenaar E, van Deemter L, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77: 491-502.
36. Schinkel AH, Wagenaar E, van Deemter L, Mol CAAM. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethazone, digoxin and cyclosporin A. J Clin Invest 1995; 96: 1698-1705.
37. Schinkel AH, Wagenaar E, Mol CAAM, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97: 2517-2524.
38. Schinkel AH, Mayer U, Wagenaar E, Mol CAAM, van Deemter L, Smit JJM, et al. Normal viability and altered phramacinetics in mice lacking mdr1-type (drug transporting) P-glycoproteins. Proc Natl Acad Sci USA 1997; 94: 4028-4033.
39. Bruggerman EP, Germann UA, Gottesman MM, Pastan I. Two different regions of phosphoglycoprotein are photoaffinity labelled by azidopine. J Biol Chem 1989; 264: 15483-15488.
40. Daoud R, Julien M, Gros P, Georges, E. Major photoaffinity drug binding sites in multidrug resistance protein 1 (MRP1) are within transmembrane domains 10-11 and 16-17. J Biol Chem 2001; 276: 12324-12330.
41. Higgins CF, Callaghan R, Linton KJ, Rosenberg MF, Ford RC. Structure of the multidrug resistance P-glycoprotein. Seminars in Cancer Biol 1997; 8: 135-142.
42. Wang E, Casciano NC, Clement RP, Johnson WW. Two transport binding sites of P-glycoprotein are unequal yet contingent: Initial rate kinetic analysis by ATP hydrolysis demonstrates intersite dependence. Biochim Biophys Acta 2000; 1481: 63-74.
43. Sauna ZE, Ambudkar SV. Characterisation of the catalytic site of ATP hydrolysis by human P-glycoprotein. J Biol Chem 2001; 276: 11553-11661.
44. Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R. Communication between multiple drug binding sites on P-glycoprotein. Mol Pharm 2000; 58: 624-632.
45. Seelig A. A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 1998; 251: 252-261.
46. Seelig A, Blatter XL, Whonsland F. Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: A comparison. Int J Clin Pharm Thera 2000; 38; 111-121.
47. Seelig A, Landwojtowicz E. Structure-activity relationship of P-glycoprotein substrates and modifiers. Eur J Pharm Sci 2000; 12: 31-40.
48. Romsicki Y, Sharom FJ The membrane lipid environment modulates drug interactions with the P-gycoprotein multidrug transporters. Biochemistry 1999; 38: 6887-6896.
49. Ekins s, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan L-B, et al. Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharm 2002; 61: 964-973.
50. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem 1993; 62: 385-427.
51. van Veen HW, Konings WN. Multidrug transporters from bacteria to man: Similarities in structure and function. Seminars in Cancer Biol 1997; 8: 183-191.
52. Österberg T, Norinder U. Theoretical calculation and prediction of P-glycprotein-interacting drugs using MolSuf parametrization and PLS statistics. Eur J Pharm Sci 2000; 10: 295-303.
53. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan L-B, et al. Application of three-dimensional quantitative structure activity relationships of P-glycoprotein inhibitors and substrates. Mol Pharm 2002; 61: 974-981.
54. Jones PM, George AM. Mechanism of ABC transporters: A molecular dynamics simulation of a well characterized nucleotide-binding subunit. Proc Natl Acad Sci USA 2002; 99: 12639-12644.
55. Mealey KL, Bentjen SA, Gay JM, Cantor GH. Ivermectin sensitivity is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics 2001; 11: 727-733.
56. Umbenhauer DR, Lankas GR, Pippert TR, Wise D, Cartwright ME, Hall S J, et al. Identification of a P-glycoprotein-deficient subpoulation in the CF-1 mouse strain using a restriction fragment length polymorphism. Tox App Pharm 1997; 146: 88-94.
57. Fromm MF. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Del Rev 2002; 54: 1295-1310.
58. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, et al. Freqeuncy of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69: 169-174.
59. Tanabe M, Ieiri I, Nagata N, Inoue I, Ito S, Kanamori Y, et al. Expression of P-glycoprotein in human placenta: Relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharm Exp Ther 2001; 297: 1137-1143.
60. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Bockmöller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-3478.
61. Furono T, Landi M-T, Ceroni M, Caporaso N. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 2001; 12: 529-534.
62. Drozdzik M, Bialecka M, Mysliwiec K, Honczarenko K, Stankeiwicz J, Sych Z. Polymorphisms in the P-glycoprotein drug transporter MDR1 gene: A possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 2003; 13: 259-263.
63. Sills GJ, Kwan P, Butler E, de Lange ECM, van den Berg D-J, Brodie MJ. P-glycoprotein-mediated efflux of antiepileptic drugs: Preliminary studies in mdra1 knockout mice. Epilepsy and Behaviour 2002; 3: 427-432.
64. Abbott NJ, Khan EU, Rollinson CMS, Reichel A, Janigro D, Dombrovski SM, et al. Drug resistance in epilepsy; The role of the blood-brain barrier. Novartis Foundation Symposium 2002; 243: 38-53.
65. Potschka H, Fedrowitz M, Lösher W. P-glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: Evidence from microdialysis experiments in rats. Neuroscience Lett 2002; 327: 173-176.
66. Sisodiya S. Mechanisms of antiepileptic drug resistance. Curr Opin Neurol 2003; 16: 197-201.
67. Marroni M, Marchi N, Cucullo L, Abbott NJ, Signorelli K, Janigro D. Vascular and parenchymal mechanisms in multiple drug resistance: A lesson from human epilepsy. Curr Drug Targets 2003; 4: 297-304.
68. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug transporter gene ABCB1. New Eng J Med 2003; 348: 1442-1448.
69. Lam FC, Liu R, Lu P, Shapiro AB, Renoir J-M, Sharom FJ, et al. β-Amyloid efflux mediated by P-glycoprotein. J Neurochem 2001; 76: 1121-1128.
70. Vogelgesang S, Cascorbi I, Schoeder E, Pahnke J, Kroemer HK, Siegmund W, et al. Deposition of Alzheimer's β-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 2002; .12: 535-541.
71. Twentyman PR, Fox NE, White DJG. Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multidrug resistant human lung cancer cell line. Br J Cancer 1987; 56: 55-57.
72. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharm Rev 1999; 42: 155-198.
73. Tamai I, Safa AR. Competitve interaction of cyclosporins with the vina alkaloid-binding site of P-glycoprotein in multidrug resistant cells. J Biol Chem 1990; 265: 16509-16513.
74. Tamai I, Safa AR. Azidopone noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells. J Biol Chem 1991; 266: 16796-16800.
75. Tsuji A, Tamai, I, Sakata A, Tenda, Y, Terasaki T. Restricted transport of cyclosporin A across the blood-brain barrier by a multidrug transporter, P-glycoprotein. Biochem Pharmacol 1993; 46: 1096-1099.
76. Begley DJ, Lechardeur D, Chen Z-D, Rolinson C, Bardoul M, Roux, F, et al. Functional expression of P-glycporotein in an immortalised cell line of rat brain endothelial cells, RBE4. J Neurochem 1996; 67: 988-995.
77. Twentyman PR, Bleehen NM. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin. Eur J cancer 1991; 27: 1639-1642.
78. Fritche E, Jensen PB, Nissen NI. Comparison of cyclosporin A and SDZ PSC833 multidrug-resistance modulators in a daunorubicin-resistant Erlich ascites tumor. Cancer Chemother Pharmacol 1992; 30: 235-237.
79. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo. reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993; 53: 4595-4602.
80. de Bruin M, Miyake K, Litman T, Robey R, Bates SE. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter MXR. Cancer Lett 1999; 146: 117-126.
81. Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH. The mouse Bcrp1/Mxr/Abcp gene: Amplification and over expression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 1999; 59: 4237-4241.
82. Letrent SP, Polack GM, Brouwer KR, Bouwer KLR. Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metab Disp 1999; 27: 827-834.
83. Jonker JW, Smit JW, Brinkhuis RF, Malipaard M, Beijnen JH, Schellens HM, et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 2000; 92: 1651-1656.
84. Evers R, Kool M, Smith AJ, van Deemter L, de Haas M, Prost P. Inhibtory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2- mediated transport. Br J Cancer 2000; 83: 366-374.
85. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg ACLM, Schinkel AH, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001; 61: 3458-3464.
86. Shepard RL, Cao, J, Starling JJ, Dantzig AH. Modulation of P-glycoprotein but not MRP1 or BCRP-mediated drug resistance by LY335979. Int J Cancer 2003; 103: 121-125.
87. Drion N, Lemaire M, Lefauconnier J-M, Scherrmann J-M. Role of P-gycoprotein in the blood-brain transport of colchicine and vinblastine. J Neurochem 1996; 67: 1688-1693.
88. Cisternino S, Rouselle C, Dagenais C, Scherrmann J-M. Screening of multidrug resistance sensitive drugs by in situ brain perfusion in P-glycoprotein deficient mice. Pharm Res 2001; 18: 183-190.
89. Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, Schinkel AH. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 1997; 100: 2430-2436.
90. Fellner S, Bauer B, Miller DS, Scaffrick M, Fankhänel M, Spruß T, et al. Transport of paclitaxel (Taxol) across the blood-brain barrier in vivo and in vitro. J Clin Invest 2002; 110: 1309-1381.
91. Kemper EM, van Zandbergen AE, Cleypool C, Mos HA, Boogerd W, Beijnen JH, et al. Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein. Clin Can Res 2003; 9: 2849-2855.
92. Lötsch J, Schmidt R, Vetter G, Schmidt H, Neiderberger E, Geisslinger G, et al. Increased CNS uptake and enhanced antinocieption of morphine-6-glucuronide in rats after inhibiton of P-glycoprotein. J Neurochem 2002 83: 241-248.
93. Savolainnen J, Edwards JE, Morgan ME, McNamara PJ, Anderson BD. Effects of a P-glycoprotein inhibitor on brain and plasma concentrations of anti-human immunodeficiencey virus drugs administered in combination in rats. Drug Metab Disp 2000; 30: 497-482.
94. Edwards JE, Brouwer KR, McNamara PJ. GF120918, a P-glycoprotein modulator, increases the concentration of unbound amprenavir in the central nervous system in rats. Antimicrobial Agents and Chemotherapy 2002; 46: 2284-2286.
95. Imbert F, Jardin M, Fernandez C, Gantier JC, Dromer F, Baron G, et al. Effect of efflux inhibition on brain uptake of itraconazole in mice infected with Cryptococcus neoformans. Drug Metab Disp 2003; 31: 319-325.
96. Choo EF, Leake B, Wandel C, Imamura H, Wood AJJ, Wilkinson GR, et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Disp 2000; 28: 655-660.
97. Tan B, Piwnica-Worms D, Ratner L. Multidrug resistance transporters and modulation. Curr Opinion in Oncology 2000; 12: 450-458.
98. Ozols R, Klecker R, Hamilton TO, Ostchega Y, Parillo JE, Young RC. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 1987: 5: 641-647.
99. Neuwelt EA, Goldman DL, Dahlborg SA, Crossen J, Ramsey F, Roman-Goldstein S, et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption; Prolonged survival and preservation of cognitive function. J Clin Oncol 1991; 9: 1580-1590.
100. Begley DJ, Brightman MW. Structural and functional aspects of the blood-brain barrier In: Prokai L, Prokai K, Eds. Basel Birkhauser Verlag. Prog in Drug Res 2003; 61: 39-78.
101. Doan KMM, Humphreys JE, Webster LD, Wring SA, Shampine LJ, Searbjit-Singh CJ, et al. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharm Exp Ther 2002; 303: 1029-1037.
102. Chisty M, Reichel A, Abbott NJ, Begley DJ. Affinity for the P-glycoprotein efflux pump at the blood-brain barrier may explain the lack of CNS side-effects of modern antihistamines. J Drug Targ 2001; 9: 223-228.
103. 1-antihistaminic agents in relation to their central side-effects. Eur J Pharm Sci 1994; 2: 373-384.
104. 3H-loradatine). Eur J Pharm Sci 1996; 4:307-319.
105. Chen C, Hanson E, Watson JW, Lee JS. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1 antagonists. Drug Metab Disp 2003; 31: 312-318.
106. Weiss J, Dorman S-VG, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE. Inhibition of P-glycoprotein by newer antidepressants. J Pharm Exp Ther 2003; 305: 197-204.
107. Lohezic-Le Devehat F, Marigny K, Doucet M, Javaudin L. Grapefruit juice and drugs: A hazardous combination? Therapie 2002; 57: 432-445.
108. Koyabu TR, Takanaga H, Matsuo H, Ohtani E, Sawada Y. effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates. Pharm Res 2002; 19: 802-809.
109. Rouselle C, Clair P, Lefauconnier J-M, Kaczorek M, Scherrmann J-M, Temsamani J. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol Pharm 2000; 57: 679-686.
110. Bodor N, Buchwald P. Brain-targeted drug delivery. Am J Drug Deliv 2003; 1: 13-26.
111. Rouselle C, Smirnova M, Clair P, Lefauconnier J-M, Chavanieu A, Calas B, et al. Enhanced delivery of doxorubicin into the brain via a peptide-based vector-mediated strategy: Saruration kinetics and specificity. J Pharm Exp Ther 2001; 296: 124-131.
112. Drin G, Cottin S, Blanc E, Rees AR, Temsamani J. Studies on the internalisation mechanism of cationic cell-penetrating peptides. J Biol Chem 2003; (In Press).
113. Mazel M, Clair P, Rouselle C, Vidal P, Scherrmann J-M, Mathieu D, et al. Doxorubicin-peptide conjugates overcome multidrug resistance. Anti-cancer Drugs 2001; 12: 107-116.
114. Kreuter J. Nanoparticle systems for brain delivery of drugs. Ad Drug Deliv Rev 2001; 47: 65-81.
115. Alyautdin R, Gothier D, Petrov V, Kharkevich D, Kreuter J. Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles. Eur J Pharm Biopharm 1995; 41: 44-48.
116. Alyautdin R, Petrov VE, Langer K, Berthold A, Kharkevich DA, Kreuter J. Delivery of loperamide across the blood-brain barrier with poly-sorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res 1995; 14: 325-328.
117. Gulyaev AE, Gelperina, SE, Skidan IN, Antopov AS, Kivman GY, Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res 1999; 16: 1564-1569.
118. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Targ 2002; 10: 317-325.
119. Pardridge WM. Drug and gene targeting to the brain with molecular Trojan horses. Nat Rev Drug Discov 2002; 1: 131-139.
120. Huwyler J, Cerlatti A, Fricker G, Eberle AN, Drewe J. By-passing of P-glycoprotein using immunoliposomes. J Drug Targ 2002; 10: 73-79.
121. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: The multidrug resistance-associated proteins. J Natnl Cancer Inst 2000; 92: 1295-1302.
122. Zhang Y, Han H, Elmquist WF, Miller DW. Expression of various multidrug resistance associated protein (MRP) homologues in brain microvessel endothelial cells. Brain Res 2000; 876: 148-153.
123. Kusuhara H, Sugiyama Y. Role of transporters in the tissue-selective distribution and eleimination of drugs: Transporters in the liver, small intestine, brain and kidney. J Contr Rel 2002; 78: 43-54.
124. Minn A, El-Bachra RDS, Bayol-Denizot C, Lagrange P, Suleman FG. Drug Metabolism in the brain: Benefits and risks. In: Begley DJ, Bradbury MW, Kreuter J. Eds. The Blood-brain barrier and drug delivery to the CNS New York, Dekker Inc. 2000; 145-170.
125. Minn A, Leclerc J-M, Heydel A-L, Minn C, Denizot C, Catarelli P, et al. Drug transport into the mammalian brain: The nasal pathway and its specific metabolic barrier. J Drug Targ 2002; 10: 285-296.
126. Kusuhara H, Suzuki H, Naito M, Tsuruo T, Sugiyama Y. Characterisation of efflux transport of organic anions in a mouse brain capillary endothelial cell line. J Pharm Exp Ther 1998; 285, 1260-1265.
127. Miller DS, Nobmann SN, Gutman H, Toeroek M, Drewe J, Fricker G. Xenobiotic transport across isolated brain micopvessels studied by confocal microscopy. Mol Pharm 2000; 58: 1357-1367.
128. Potschka H, Fedrowitz M, Löscher W. Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J Pharm Exp Ther 2003; 306: 124-131.
129. Wijnholds J, de Lange ECM, Scheffer GL, van den Berg D-J, Mol CAAM, van der Valk M, et al. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J Clin Invest 2000; 105: 279-285.
130. Cisternino S, Rouselle C, Lorico A, Rappa G, Schermann J-M. Apparent lack of Mrp1-mediated efflux at the luminal side of mouse blood-brain barrier endothelial cells. Pharm Res 2003; 20: 904-909.
131. Gerk PM, Vore M. Regulation of expression of the multidrug resistance-associated protein 2 (MRP2) and its role in drug disposition. J Pharm Exp Ther 2002; 302: 407-415.
132. Draper MP, Martell RL, Levy SB. Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein. Br J Cancer 1997; 75: 810-815.
133. Suzuki H, Sugiyama Y. Single polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): Its impact on drug disposition. Adv Drug Del Rev 2002; 54: 1311-1331.
134. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi A, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998; 95: 15665-15670.
135. Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, et al. The multidrug-resistant phenotype associated with overexpresion of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 2000; 113: 2011-2021.
136. Özvegy C, Litman T, Szakács G, Nagy Z, Bates S, Váradi A, et al. Functional characterisation of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Comm 2001; 285: 111-117.
137. Eisenblätter T, Hüwel S, Galla H-J. Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier. Brain Res 2003; 971: 221-231.
138. Maliepaard M, van Gastelen MA, Tohgo A, Hausheer FH, van Waardenberg Rc, de Jong, LA, et al. Circumvention of breast cancer resistance proteins (BRCP) resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF129918. Clin Can Res 2001; 7: 935-941.
139. Rabidran SK, He H, Singh M, Brown E, Collins KI, Annable T, et al. Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res 1998; 58: 5850-5858.
140. Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberger LM. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 2000; 60: 47-50.
141. van Loevezijn A, Allen JD, SchinkelAH, Koomen GJ. Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines. Bioorg Med Chem Lett 2001; 11: 29-32.
142. Brangi M, Litman T, Ciotti M, Nishiyama K, Kohlhagen G, Takimoto C, et al. Camptothecin resistance: Role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 1999; 59: 5938-5946.
143. Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW, van der Laar A, et al. Acquired mutatins in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 2001; 61: 6635-6639.
144. Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T, et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 2002; 1: 611-616.
145. Banks WA. Is obesity a disease of the blood-brain barrier? Physiological, pathological, and evolutionary considerations. Curr Pharm Design 2003; 9(10): 801-9.
146. Gero AM, Dunn CG, Brown DM, Pulenthiran K, Gorovits EL, Bakos T, et al. New malaria chemotherapy developed by utilization of a unique parasite transport system. Curr Pharm Design 2003; 9(11): 867-77.
147. Pan W, Kastin AJ. Interactions of cytokines with the blood-brain barrier: implications for feeding. Curr Pharm Design 2003; 9(10): 827-31.